ImpriMed Launches New Diagnostic Services for Canine Lymphoma PALO ALTO, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading functional precision medicine company in veterinary oncology that provides a personalized drug response profiling...

ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma PALO ALTO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading veterinary precision medicine biotech startup today announced the launching of their most advanced precision medicine...

ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading veterinary precision medicine startup has recently closed a total of $8 million in Pre-Series A funding with $7.7...

ImpriMed Raises $4M for Customized Cancer Treatments for Dogs PALO ALTO, Calif., April 12, 2019 (GLOBE NEWSWIRE) -- ImpriMed, the cutting edge creator and researcher of custom, precision cancer treatment for canines, announced today that it has raised a total...